Tirdzniecība Pluri Inc. - PLUR CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Starpība | 0.0326 | ||||||||
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.030779% | ||||||||
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | -0.013666% | ||||||||
Nakts laika nodeva | 22:00 (UTC) | ||||||||
Min. tirgotais daudzums | 1 | ||||||||
Valūta | USD | ||||||||
Drošības rezerve | 20% | ||||||||
Fondu birža | United States of America | ||||||||
Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Iepriekš. aizvērt* | 1.1187 |
Atvērt* | 1.1187 |
Izmaiņas par 1 gadu* | -33.01% |
Dienas Diapazons* | 1.0587 - 1.1287 |
52 ned Diapazons | 0.65-2.21 |
Vidējais apjoms (10 dienas) | 30.38K |
Vidējais apjoms (3 mēneši) | 1.47M |
Tirgus Kapitalizācija | 34.94M |
Cenas/Peļņas Attiecība | -100.00K |
Izvietotās Akcijas | 32.66M |
Ieņēmumi | 321.00K |
EPS | -1.12 |
Dividende (Ienesīgums %) | N/A |
Beta | 1.60 |
Nākamās Peļņas Datums | N/A |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
---|---|---|---|---|---|---|
Feb 3, 2023 | 1.0587 | -0.0600 | -5.36% | 1.1187 | 1.1287 | 1.0587 |
Feb 2, 2023 | 1.1187 | 0.0200 | 1.82% | 1.0987 | 1.1187 | 1.0787 |
Jan 27, 2023 | 1.1187 | -0.0299 | -2.60% | 1.1486 | 1.1586 | 1.1087 |
Jan 26, 2023 | 1.1287 | 0.0100 | 0.89% | 1.1187 | 1.1287 | 1.1187 |
Jan 25, 2023 | 1.0887 | 0.0000 | 0.00% | 1.0887 | 1.0887 | 1.0887 |
Jan 24, 2023 | 1.1586 | 0.0000 | 0.00% | 1.1586 | 1.1686 | 1.1586 |
Jan 20, 2023 | 1.1586 | -0.0400 | -3.34% | 1.1986 | 1.1986 | 1.1586 |
Jan 19, 2023 | 1.2286 | 0.0200 | 1.65% | 1.2086 | 1.2585 | 1.1686 |
Jan 18, 2023 | 1.2785 | 0.0599 | 4.92% | 1.2186 | 1.2785 | 1.2186 |
Jan 17, 2023 | 1.2585 | 0.0799 | 6.78% | 1.1786 | 1.3285 | 1.1786 |
Jan 13, 2023 | 1.2086 | 0.1399 | 13.09% | 1.0687 | 1.3984 | 1.0687 |
Jan 12, 2023 | 1.0288 | 0.0000 | 0.00% | 1.0288 | 1.0687 | 1.0288 |
Jan 11, 2023 | 1.0088 | -0.0200 | -1.94% | 1.0288 | 1.0288 | 1.0088 |
Jan 9, 2023 | 1.0288 | 0.0300 | 3.00% | 0.9988 | 1.0588 | 0.9988 |
Jan 6, 2023 | 0.9986 | 0.0435 | 4.55% | 0.9551 | 1.0288 | 0.9551 |
Jan 5, 2023 | 0.9550 | -0.0299 | -3.04% | 0.9849 | 0.9850 | 0.9489 |
Jan 4, 2023 | 0.9987 | 0.0039 | 0.39% | 0.9948 | 0.9988 | 0.9948 |
Jan 3, 2023 | 0.9916 | 0.0067 | 0.68% | 0.9849 | 0.9985 | 0.9788 |
Dec 30, 2022 | 0.9352 | -0.0065 | -0.69% | 0.9417 | 0.9489 | 0.9352 |
Dec 29, 2022 | 0.9277 | -0.0175 | -1.85% | 0.9452 | 0.9551 | 0.9203 |
Pluri Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Ikgadējs
- Ceturkšņa
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Kopējie ienākumi | 2.847 | 0 | 0.05 | 0.054 | 0.023 | 0 |
Ienākumi | 2.847 | 0 | 0.05 | 0.054 | 0.023 | 0 |
Cost of Revenue, Total | 0.1 | 0 | 0.002 | 0.002 | 0 | 0 |
Bruto Peļņa | 2.747 | 0 | 0.048 | 0.052 | 0.023 | 0 |
Kopējie Darbības Izdevumi | 26.166 | 28.019 | 33.781 | 35.586 | 29.499 | 50.623 |
Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 6.486 | 6.927 | 11.193 | 9.157 | 7.922 | 20.557 |
Pētniecība un Attīstība | 20.85 | 21.972 | 24.478 | 12.841 | 21.643 | 13.47 |
Depreciation / Amortization | 2.006 | 2.029 | 1.893 | 1.841 | 1.453 | 1.252 |
Other Operating Expenses, Total | -3.276 | -2.909 | -3.785 | 11.745 | -1.519 | 15.344 |
Darbības Izdevumi | -23.319 | -28.019 | -33.731 | -35.532 | -29.476 | -50.623 |
Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | 0.109 | 0.272 | 8.542 | 0.105 | 0.356 | 0.781 |
Citi, Neto | -0.036 | -0.067 | -0.937 | 0.12 | -0.032 | -0.023 |
Neto Ienākumi Pirms Nodokļu Nomaksas | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
Neto Ienākumi Pēc Nodokļu Nomaksas | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
Neto Ienākumi Pirms Ārkārtas Posteņiem | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
Neto Ienākumi | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
Atšķaidītie Neto Ienākumi | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
Atšķaidītie Ienākumi par Akcijām | 7.9548 | 8.74262 | 10.5877 | 1.23329 | 18.1973 | 28.1136 |
Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -2.92226 | -3.18143 | -2.46759 | -28.6283 | -1.602 | -1.77369 |
Dividends per Share - Common Stock Primary Issue | 0 | |||||
Atšķaidītā Normalizētā Peļņa par Akciju | -2.85237 | -3.12149 | -2.38995 | -28.1158 | -1.5688 | -1.74709 |
Q3 2021 | Q4 2021 | Q1 2021 | Q2 2021 | Q3 2022 | |
---|---|---|---|---|---|
Kopējie ienākumi | 0 | 0 | 0 | 0 | 0.234 |
Ienākumi | 0 | 0 | 0.234 | ||
Cost of Revenue, Total | 0 | 0 | |||
Bruto Peļņa | 0 | 0 | |||
Kopējie Darbības Izdevumi | 14.225 | 14.587 | 11.441 | 10.795 | 10.709 |
Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 6.559 | 6.102 | 5.088 | 4.288 | 4.553 |
Pētniecība un Attīstība | 7.824 | 8.507 | 6.391 | 6.541 | 6.273 |
Other Operating Expenses, Total | -0.158 | -0.022 | -0.038 | -0.034 | -0.117 |
Darbības Izdevumi | -14.225 | -14.587 | -11.441 | -10.795 | -10.475 |
Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -0.029 | 0.019 | 0.009 | -0.145 | 0.557 |
Neto Ienākumi Pirms Nodokļu Nomaksas | -14.254 | -14.568 | -11.432 | -10.94 | -9.918 |
Neto Ienākumi Pēc Nodokļu Nomaksas | -14.254 | -14.568 | -11.432 | -10.94 | -9.918 |
Neto Ienākumi Pirms Ārkārtas Posteņiem | -14.254 | -14.568 | -11.432 | -10.94 | -9.918 |
Neto Ienākumi | -14.254 | -14.568 | -11.432 | -10.94 | -9.918 |
Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -14.254 | -14.568 | -11.432 | -10.94 | -9.918 |
Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -14.254 | -14.568 | -11.432 | -10.94 | -9.918 |
Atšķaidītie Neto Ienākumi | -14.254 | -14.568 | -11.432 | -10.94 | -9.918 |
Atšķaidītie Ienākumi par Akcijām | 29.6172 | 31.6441 | 32.0008 | 32.1363 | 32.2616 |
Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -0.48127 | -0.46037 | -0.35724 | -0.34042 | -0.30742 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Atšķaidītā Normalizētā Peļņa par Akciju | -0.48127 | -0.46037 | -0.35724 | -0.34042 | -0.30742 |
- Ikgadējs
- Ceturkšņa
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Apgrozāmo Līdzekļu Kopsumma | 35.596 | 29.016 | 32.036 | 26.371 | 48.461 | 67.371 |
Nauda un Īstermiņa Ieguldījumi | 32.208 | 26.106 | 29.9 | 23.705 | 45.784 | 64.95 |
Nauda un Ekvivalenti | 6.223 | 4.707 | 8.821 | 4.106 | 8.27 | 31.241 |
Īstermiņa Ieguldījumi | 25.985 | 21.399 | 21.079 | 19.599 | 37.514 | 33.709 |
Debitoru Parādu Kopsumma, Neto | 2.481 | 1.174 | 0.847 | 1.421 | 1.61 | 1.49 |
Accounts Receivable - Trade, Net | 2.251 | 1.036 | 0.69 | 1.243 | 1.248 | 1.108 |
Prepaid Expenses | 0.3 | 0.882 | 0.602 | 0.532 | 0.445 | 0.333 |
Other Current Assets, Total | 0.607 | 0.854 | 0.687 | 0.713 | 0.622 | 0.598 |
Total Assets | 45.941 | 37.534 | 38.96 | 31.31 | 65.532 | 93.538 |
Property/Plant/Equipment, Total - Net | 9.216 | 7.277 | 5.678 | 3.838 | 3.775 | 2.227 |
Property/Plant/Equipment, Total - Gross | 17.183 | 16.507 | 16.893 | 17.004 | 18.437 | 18.259 |
Accumulated Depreciation, Total | -7.967 | -9.23 | -11.215 | -13.166 | -14.662 | -16.032 |
Long Term Investments | 0.363 | 0.403 | 0.383 | 0.398 | 12.653 | 23.269 |
Other Long Term Assets, Total | 0.766 | 0.838 | 0.863 | 0.703 | 0.643 | 0.671 |
Total Current Liabilities | 5.775 | 5.414 | 8.548 | 8.158 | 7.987 | 11.517 |
Accounts Payable | 2.705 | 1.966 | 3.261 | 2.281 | 1.968 | 2.526 |
Accrued Expenses | 2.819 | 3.106 | 4.164 | 5.637 | 5.893 | 8.951 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.251 | 0.342 | 1.123 | 0.24 | 0.126 | 0.04 |
Total Liabilities | 7.785 | 7.283 | 10.453 | 9.489 | 9.431 | 36.387 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 | 23.85 |
Other Liabilities, Total | 2.01 | 1.869 | 1.905 | 1.331 | 1.444 | 1.02 |
Total Equity | 38.156 | 30.251 | 28.507 | 21.821 | 56.101 | 57.151 |
Common Stock | 0.001 | 0.001 | 0.001 | 0.001 | ||
Additional Paid-In Capital | 198.432 | 217.822 | 244.203 | 272.824 | 336.257 | 387.172 |
Retained Earnings (Accumulated Deficit) | -161.757 | -189.571 | -215.697 | -251.004 | -280.156 | -330.021 |
Unrealized Gain (Loss) | 1.48 | 1.48 | 8.44 | |||
Other Equity, Total | 0 | 0.519 | -8.44 | |||
Total Liabilities & Shareholders’ Equity | 45.941 | 37.534 | 38.96 | 31.31 | 65.532 | 93.538 |
Total Common Shares Outstanding | 8.0269 | 9.69388 | 11.3566 | 15.0829 | 25.4927 | 31.9578 |
Long Term Debt | 23.85 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Apgrozāmo Līdzekļu Kopsumma | 49.82 | 67.371 | 62.826 | 60.153 | 64.313 |
Nauda un Īstermiņa Ieguldījumi | 47.37 | 64.95 | 60.671 | 58.183 | 61.98 |
Nauda un Ekvivalenti | 12.265 | 31.241 | 14.611 | 18.715 | 23.791 |
Īstermiņa Ieguldījumi | 35.105 | 33.709 | 46.06 | 39.468 | 38.189 |
Other Current Assets, Total | 2.45 | 2.421 | 2.155 | 1.97 | 2.333 |
Total Assets | 79.174 | 93.538 | 83.747 | 81.184 | 79.127 |
Property/Plant/Equipment, Total - Net | 2.713 | 2.227 | 1.749 | 9.331 | 9.14 |
Long Term Investments | 25.937 | 23.269 | 18.483 | 10.965 | 4.235 |
Other Long Term Assets, Total | 0.704 | 0.671 | 0.689 | 0.735 | 1.439 |
Total Current Liabilities | 9.916 | 11.517 | 10.365 | 9.595 | 7.822 |
Accounts Payable | 2.11 | 2.526 | 3.723 | 4.058 | 3.942 |
Accrued Expenses | 5.613 | 6.575 | 6.642 | 5.537 | 3.88 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 2.193 | 2.416 | |||
Total Liabilities | 11.038 | 36.387 | 34.84 | 41.344 | 41.034 |
Total Long Term Debt | 0 | 23.85 | 23.444 | 23.158 | 22.924 |
Other Liabilities, Total | 1.122 | 1.02 | 1.031 | 8.591 | 8.238 |
Total Equity | 68.136 | 57.151 | 48.907 | 39.84 | 38.0933 |
Additional Paid-In Capital | 383.589 | 387.172 | 390.36 | 392.233 | 400.351 |
Retained Earnings (Accumulated Deficit) | -315.453 | -330.021 | -341.453 | -352.393 | -362.258 |
Total Liabilities & Shareholders’ Equity | 79.174 | 93.538 | 83.747 | 81.184 | 79.1273 |
Total Common Shares Outstanding | 31.7402 | 31.9578 | 32.0969 | 32.2251 | 32.3424 |
Debitoru Parādu Kopsumma, Neto | 0 | ||||
Accounts Receivable - Trade, Net | 0 | ||||
Current Port. of LT Debt/Capital Leases | 0 | ||||
Long Term Debt | 23.85 | 23.444 | 23.158 | 22.924 | |
Common Stock | 0.00032 | 0.00032 | |||
Other Equity, Total | -0.00032 | ||||
Minority Interest | 2.05 |
- Ikgadējs
- Ceturkšņa
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Neto ienākumi/Sākuma Līnija | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
Nauda no Darbības | -18.522 | -21.611 | -21.38 | -29.453 | -26.369 | -30.91 |
Nauda no Darbības | 2.15 | 2.177 | 2.018 | 1.962 | 1.57 | 1.37 |
Bezskaidras Naudas Preces | 3.498 | 4.174 | -1.025 | 5.146 | 2.562 | 13.968 |
Cash Taxes Paid | 0.066 | 0.028 | 0.027 | 0.01 | 0.01 | |
Izmaiņas Apgrozāmajā Kapitālā | -0.924 | -0.148 | 3.753 | -1.254 | -1.349 | 3.617 |
Nauda no Ieguldījumu Darbībām | 1.312 | 4.355 | 5.681 | 1.17 | -30.458 | -7.265 |
Kapitālie Izdevumi | -1.75 | -0.378 | -0.342 | -0.239 | -0.27 | -0.373 |
Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | 3.062 | 4.733 | 6.023 | 1.409 | -30.188 | -6.892 |
Nauda no Darbībām ar Finansēšanu | 0.807 | 15.797 | 19.921 | 23.582 | 60.87 | 61.402 |
Akciju Izsniegšana (Atkāpšanās), Neto | 0.807 | 15.728 | 19.833 | 23.475 | 60.87 | 36.953 |
Neto Izmaiņas Naudā | -16.403 | -1.459 | 4.222 | -4.701 | 4.043 | 22.609 |
Naudas Plūsma Finansēšanas Posteņos | 0.069 | 0.088 | 0.107 | 0 | ||
Parādu Izsniegšana (Atkāpšanās), Neto | 24.449 | |||||
Ārvalstu Valūtas Ietekme | -0.618 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -35.297 | -49.865 | -11.432 | -22.372 | -32.29 |
Cash From Operating Activities | -21.313 | -30.91 | -8.789 | -18.652 | -28.074 |
Cash From Operating Activities | 1.034 | 1.37 | 0.337 | 0.664 | 0.915 |
Non-Cash Items | 10.382 | 13.968 | 3.188 | 6.1 | 7.782 |
Cash Taxes Paid | 0.008 | ||||
Changes in Working Capital | 2.568 | 3.617 | -0.882 | -3.044 | -4.481 |
Cash From Investing Activities | -12.057 | -7.265 | -7.24 | 7.075 | 14.738 |
Capital Expenditures | -0.331 | -0.373 | -0.015 | -0.044 | -0.081 |
Other Investing Cash Flow Items, Total | -11.726 | -6.892 | -7.225 | 7.119 | 14.819 |
Cash From Financing Activities | 36.992 | 61.402 | 0 | 0 | 7.5 |
Issuance (Retirement) of Stock, Net | 36.992 | 36.953 | 0 | 0 | 0 |
Net Change in Cash | 3.622 | 22.609 | -16.62 | -12.616 | -6.908 |
Issuance (Retirement) of Debt, Net | 24.449 | ||||
Foreign Exchange Effects | -0.618 | -0.591 | -1.039 | -1.072 | |
Financing Cash Flow Items | 7.5 |
Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
---|---|---|---|---|---|---|
Yanay (Yaky) | Individual Investor | 3.2937 | 1075620 | 396790 | 2022-12-22 | LOW |
Regals Capital Management, L.P. | Investment Advisor | 3.2824 | 1071938 | 1071938 | 2022-01-24 | |
Aberman (Zalman) | Individual Investor | 2.5434 | 830604 | -2000 | 2022-12-20 | LOW |
Slager (David M) | Individual Investor | 1.8774 | 613100 | 613100 | 2022-01-24 | HIGH |
Meitav Dash Investments Ltd. | Investment Advisor | 0.5132 | 167593 | 0 | 2022-09-30 | LOW |
Nia Impact Capital | Investment Advisor | 0.4071 | 132947 | -318394 | 2022-09-30 | LOW |
Susquehanna International Group, LLP | Investment Advisor | 0.3235 | 105657 | -174105 | 2022-09-30 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.3197 | 104400 | -2900 | 2022-09-30 | HIGH |
Bridgeway Capital Management, LLC | Investment Advisor | 0.3142 | 102600 | -10000 | 2022-09-30 | LOW |
Nikko Asset Management Americas, Inc. | Investment Advisor/Hedge Fund | 0.2574 | 84056 | -20865 | 2021-12-31 | LOW |
Franco-Yehuda (Chen) | Individual Investor | 0.225 | 73466 | 6875 | 2022-12-21 | LOW |
Green Alpha Advisors, LLC | Investment Advisor | 0.1794 | 58603 | 2377 | 2022-12-31 | HIGH |
Values First Advisors, Inc. | Investment Advisor | 0.1398 | 45653 | -2677 | 2022-12-31 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.1211 | 39544 | 0 | 2022-12-31 | LOW |
Jane Street Capital, L.L.C. | Research Firm | 0.1102 | 35986 | -46524 | 2022-09-30 | HIGH |
Group One Trading, L.P. | Research Firm | 0.0877 | 28638 | -5900 | 2022-09-30 | HIGH |
Zürcher Kantonalbank (Asset Management) | Bank and Trust | 0.0842 | 27497 | -137 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.0771 | 25169 | 0 | 2022-09-30 | LOW |
Millennium Management LLC | Hedge Fund | 0.0625 | 20412 | -120303 | 2022-09-30 | HIGH |
Archford Capital Strategies, LLC | Investment Advisor | 0.0401 | 13091 | 0 | 2022-12-31 | LOW |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com GroupTirgotāji
Ikmēneša aktīvie klienti
Ikmēneša ieguldījumu apjoms
Izņemts katru mēnesi
Treidinga kalkulators
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Pluri Inc. Company profile
Par Pluristem Therapeutics Inc.
Uzņēmums Pluristem Therapeutics Inc. izstrādā placentas šūnu terapijas produktus vairāku išēmisku, iekaisuma un hematoloģisku slimību ārstēšanai. Uzņēmuma galvenās indikācijas ir kritiskā ekstremitāšu išēmija (CLI), atveseļošanās pēc operācijas pēc augšstilba kaula kakla lūzuma gadījumā un akūts radiācijas sindroms. Uzņēmuma darbība ir vērsta uz šūnu terapijas un saistīto tehnoloģiju pētniecību, izstrādi, klīniskajiem izmēģinājumiem un ražošanu. Uzņēmuma produkti ir PLX-PAD un PLX R18. Uzņēmuma PLX šūnas ir adherentās stromālās šūnas (ASC), kas tiek paplašinātas, izmantojot trīsdimensiju (3D) procesu. Sistēma izmanto sintētisku karkasu, lai radītu mākslīgu 3D vidi, kurā var augt no placentas atvasinātas stromālās šūnas. Uzņēmuma PLX produkti tiek ievadīti, izmantojot standarta adatu un šļirci. Uzņēmuma PLX produkti ir klīniskās izstrādes stadijā attiecībā uz vairākām indikācijām, piemēram, sirds un asinsvadu, ortopēdiskām, plaušu un sieviešu veselības slimībām.
Industry: | Biotechnology & Medical Research (NEC) |
MATAM Advanced Technology Park
Building #5
3508409
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 485 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com